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Abstract
Background: We know little about the budget impact of integrating robotic exoskeleton over-ground training into
therapy services for locomotor training. The purpose of this study was to estimate the budget impact of adding
robotic exoskeleton over-ground training to existing locomotor training strategies in the rehabilitation of people
with spinal cord injury.
Methods: A Budget Impact Analysis (BIA) was conducted using data provided by four Spinal Cord Injury (SCI) Model
Systems rehabilitation hospitals. Hospitals provided estimates of therapy utilization and costs about people with spinal
cord injury who participated in locomotor training in the calendar year 2017. Interventions were standard of care
walking training including body-weight supported treadmill training, overground training, stationary robotic systems
(i.e., treadmill-based robotic gait orthoses), and overground robotic exoskeleton training. The main outcome measures
included device costs, training costs for personnel to use the device, human capital costs of locomotor training, device
demand, and the number of training sessions per person with SCI.
Results: Robotic exoskeletons for over-ground training decreased hospital costs associated with delivering locomotor
training in the base case analysis. This analysis assumed no difference in intervention effectiveness across locomotor
training strategies. Providing robotic exoskeleton overground training for 10% of locomotor training sessions over the
course of the year (range 226–397 sessions) results in decreased annual locomotor training costs (i.e., net savings)
between $1114 to $4784 per annum. The base case shows small savings that are sensitive to parameters of the BIA
model which were tested in one-way sensitivity analyses, scenarios analyses, and probability sensitivity analyses. The base
case scenario was more sensitive to clinical utilization parameters (e.g., how often devices sit idle and the substitution of
high cost training) than device-specific parameters (e.g., robotic exoskeleton device cost or device life). Probabilistic
sensitivity analysis simultaneously considered human capital cost, device cost, and locomotor device substitution. With
probabilistic sensitivity analysis, the introduction of a robotic exoskeleton only remained cost saving for one facility.
Conclusions: Providing robotic exoskeleton for over-ground training was associated with lower costs for the locomotor
training of people with SCI in the base case analyses. The analysis was sensitive to parameter assumptions.
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Background
Between 249,000 to 363,000 persons live with disabilities
due to spinal cord injuries (SCI) in the United States, and
approximately 17,730 individuals experience new SCI each
year [1]. The average age of SCI onset is 43 years, affording
the opportunity to resume active community involvement
and employment. Despite strong incentives to resume
activities, much depends on the restoration of upper and
lower limb function. The inability to stand and walk not
only limits community involvement and employment but
these functional limitations also impose significant second-
ary health conditions. These conditions include depression,
pressure ulcers, severe spasticity, pain, limited joint range of
motion, contractures, muscle atrophy, bone loss, and
impaired digestive, respiratory, renal, and cardiovascular
function [2]. Each condition markedly reduces health and
quality of life of persons with SCI. In addition to the phys-
ical burden, spinal cord injury accounts for significant
health care costs ranging from $368,562 to $1,129,302 in
first year costs and $44,766 to $196,107 in annual health
care costs depending on the severity of injury [1].
For most individuals, some form of functional limitation
persists; however, improvement in mobility and function
is possible following the injury. The preservation of vol-
itional motor or sensory function below the lesion level
provides an opportunity for motor recovery from intensive
training during rehabilitation. This population has great
potential for motor recovery and walking. Locomotor
training is a standard of care for the rehabilitation of the
individual with incomplete SCI. Likewise, walking is usu-
ally one of the primary goals of rehabilitation due to
physiological and social benefits [3, 4].
Conventional locomotor training strategies include those
in which body-weight is supported while clinicians may
manually facilitate stepping motions. This training requires
multiple personnel to assist with support or lower extremity
movement. Although body-weight supported treadmill train-
ing (BWSTT) and overground training (OGT) remain com-
mon locomotor training strategies, alternative strategies
using robotic therapy (RT) devices require less human capital
and allow greater repetition than typically is delivered in
personnel-intensive approaches [5]. RT may enhance thera-
pists’ productivity and effectiveness while facilitating neuro-
logical recovery [5]. RT devices have several advantages,
including a structure that provides stability, programmable
force-production that facilitates lower extremity movement,
[6, 7] precise measurement of forces, [5, 7, 8] and the ability
to perform repetitive, labor-intensive tasks [9, 10]. A limita-
tion of many RT devices is their limited interaction with the
external environment. Many are stationary and only serve as
a tool for the promotion of neural recovery or exercise.
Robotic exoskeletons (RT-exo) are prescription devices
comprising an external, motorized orthosis that is placed
over paralyzed or weakened limbs for the purpose of
facilitating standing, walking, climbing stairs, and per-
forming activities of daily living [11, 12]. Exoskeletons
can be used at home, at work, and during rehabilitation
[13]. Thus, RT-exo may serve the therapeutic role pro-
posed by stationary robotic devices [14] while allowing
mobility and more active community involvement.
Clinical efficacy
Multiple randomized trials have found outcomes associated
with RT to be no different from conventional therapy when
similar doses are compared [15–20];; however, a recent
meta-analysis of studies investigating RT in individuals with
SCI found greater improvement for walking independence
(3.73; 95% confidence interval [CI], − 4.92 to − 2.53;
P < .00001) and endurance (53.32m; 95% CI, − 73.15 to −
33.48; P < .00001) in robot-assisted training groups [21].
Additional systematic reviews found improvement in loco-
motor recovery using robot-assisted therapy following SCI
[22]. Tefertiller and colleagues reported that RT is likely to
be at least as effective as therapy alternatives for locomotor
training for individuals with neurological injuries and dis-
eases [14, 22]. Whereas RT-exo has less evidence supporting
its use versus treadmill-based RT, several pilot studies of RT-
exo have recently been published with preliminary evidence
of efficacy [10, 23]. Sale et al. used a prospective, quasi-
experimental study, pre-post design and found that RT-exo
training resulted in significant improvements in timed up-
and-go (TUG), six minute walk test (6MWT), and ten meter
walk test (10MWT) [23]. Chang et al. randomized patients
to RT-exo versus conventional physical therapy and found
the RT-exo group to increase significantly in 6MWT, stride
length, and step length after the intervention [10].
RT-exo shares many of the features of treadmill-based
RT devices while allowing greater user autonomy and fewer
environmental restrictions than treadmill-based RT devices
[13]. A recent qualitative study of gym-based RT-exo users
identified themes supporting improved community integra-
tion [24]; however in a recent narrative overview of RT-exo,
the authors critiqued four RT-exo devices, suggesting that
they fall short of promises to reengage in activities set in
real-world contexts [25]. Furthermore, the authors suggest
that RT-exo is better suited for rehabilitation settings than
in home settings [25].
Cost considerations of new technology
New technology in health care is a substantial contributor to
rising costs, [26] creating tensions as different stakeholders
in the health care sector interpret the value added by the
new technology [27]. Health funders attempt to balance cost
control, access to treatment, and support for innovation.
Health technology producers seek financial reward for their
innovations and to fund further development. Patients and
clinicians perceive the new technology in terms of benefits
produced for the individual [26, 28]. In 1991, Neumann and
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Weinstein [29] identified ‘five facts’ of new medical tech-
nologies that remain true today:
1. On average new technologies improve health outcomes
2. Many new technologies do not improve health
outcomes and it is not always easy to discriminate
between effective and ineffective technologies.
3. On average new technologies add to health care costs
4. Diffusion of new technology often is inefficient
5. Demand for new technology almost always is high.
The rapid growth and development of robotic devices is
an excellent example of such a technology in rehabilitation.
The costs of robotic exoskeletons include a high initial pur-
chase price (relative to competing rehabilitation technology),
annual maintenance costs, and training costs per physical
therapist user. Whereas many new technologies can be cost-
inefficient, others have been shown to be cost-neutral or
cost-saving [26]. It has been suggested that there is potential
for new robotic technology in rehabilitation to be cost saving
if the cost of a robotic system could be offset by a decreased
need for rehabilitation personnel to conduct the labor-
intensive demands of rehabilitation [30]. Whereas robotic
exoskeletons initially have been considered a research tool
and a device for individual users intent on community use,
the robotic exoskeleton is less expensive than stationary ro-
botic devices and may be an attractive option for rehabilita-
tion hospitals as a device for training. An unfortunate reality
of technology is the delay between the rising clinical evidence
and the rate at which reimbursement changes to account for
the costs of technology [31].
Budget impact analysis – framework
We know little about the budget impact of integrating RT-
exo devices into routine therapy services. Carpino et al.
conducted a review and model-based cost-effectiveness
analysis of lower extremity robotics, showing RT-exo to be
cost-effective relative to conventional care and stationary
robotics; however, model assumptions have been criticized
[32]. Morrison performed an analysis of the financial feasi-
bility of lower extremity robotics, but did not address
exoskeletal devices [33]. No budget impact analysis was
performed for RT-exo in these economic studies. A budget
impact analysis (BIA) provides a framework for synthesiz-
ing knowledge when healthcare systems wish to estimate
the financial consequences of purchasing new technology
[34]. A BIA is not designed to provide a single estimate ap-
plicable to all decision-makers, but instead reflects local
health systems’ environment and decision-makers’ varying
perspectives [34]. For the purpose of this study, we evaluate
a model that reflects the introduction or expansion of RT-
exo on the total health system budget at four model health
systems with different case mixes.
Methods
BIA framework and conceptual model for SCI
Estimation of the budgetary impact of a new intervention
involves a comparison of the “world without” against the
“world with” an RT-exo locomotor strategy. The net differ-
ence in estimated health-care costs between these two sce-
narios constitutes the budgetary impact of the intervention.
The BIA framework takes into consideration health system
features, population eligibility, and resource use in order to
understand what current and future costs are for the treat-
ment of a given condition (Fig. 1).
Figure 2 presents the conceptual model for the application
of BIA to SCI locomotor strategies, where individuals enter
into a rehabilitation facility following SCI and acute medical
management. Locomotor training strategies are part of what
constitutes rehabilitation following SCI for many patients.
Other rehabilitative services include physical medicine and
rehabilitation services, occupational therapy, social work,
vocational rehabilitation, and psychological services. For the
purposes of this analysis, we assume that all other services
remain unchanged with the substitution of RT-exo services
for other locomotor training strategies.
The perspective of the analysis is from the rehabilitation fa-
cilities, specifically Inpatient Rehabilitation Facilities and
Long Term Care Hospitals, as the purchasers of technology.
A retrospective pre-post study design was implemented to
estimate the treatment cost of locomotor strategies. The
budget impact of RT-exo was evaluated over one year. The
calculation was replicated in a Microsoft Excel-based spread-
sheet. Probabilistic sensitivity analysis was conducted using R
Statistical Software [35].
Four SCI Model Systems agreed to collaborate on this
project: [1] The Shirley Ryan AbilityLab (formerly the
Rehabilitation Institute of Chicago), [2] Craig Hospital,
[3] Shepherd Center, and [4] TIRR Memorial Hermann.
Participating model system sites served as the primary
data source for estimates of resource utilization.
Model inputs
The base case scenario represents the most likely or pre-
ferred set of assumptions, and sensitivity analyses explore
deviations for this estimate [36]. Our base case model as-
sumptions are presented in Tables 1-3 and Appendix 1.
Table 1 presents facility characteristics, estimated number
of individuals with SCI receiving locomotor training dur-
ing the inclusion time period, and locomotor training
strategies considered in this exercise. We estimated cost
and utilization data from participating Model System sites,
details of unit costs and associated sources are included in
Appendix 1. The number of individuals with SCI who
were estimated to have received locomotor training was
multiplied by the average number of training sessions per
facility. The total number of training sessions per year was
then multiplied by the proportion of training sessions
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Fig. 2 Budget Impact Analysis Conceptual Model for Locomotor Training Market Share
Fig. 1 Budget Impact Analysis Schematic
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devoted to available locomotor strategies, yielding the
number of locomotor sessions per strategy per year. Salary
data were populated from the Bureau of Labor Statistics
website (https://www.bls.gov/bls/blswage.htm) according
to the model system facility location.
Table 2 reports BIA inputs and key assumptions concern-
ing the device costs, training costs, and human capital costs
associated with locomotor training in inpatient rehabilitation
facilities. Where facilities provided more specific data for the
analysis, we adapted the inputs accordingly. The duration of
all training sessions was assumed to be one hour, including
set-up time. We assumed all devices had an adoption rate of
50% across clinicians (i.e., the robotic device sits idle 50% of
the time). The adoption rate represents the rate at which
the new technology is accepted and the demand for the
locomotor training device. We are using assumptions for
training session time and adoption rate because RT-exo
currently is not used for treatment across facilities.
Table 3 reports the changes in locomotor training
strategies between the current and future market share
of locomotor strategies within the respective hospital
systems. The Appendix provides greater detail of BIA in-
puts with costs in 2017 USD.
Sensitivity analysis
Several parameters are likely to influence the RT-exo BIA,
including device cost, the choice of locomotor strategy for
substitution, and the efficiency of the use of RT-exo. One
way sensitivity analyses will vary the following parameters:
cost of robotic exoskeleton (50, 200%), adoption rate of
robotic exoskeleton device (100–10%), training strategy
substituted (highest cost training substituted, lowest cost
training substituted), and exoskeleton device life (8 year de-
vice life – 3 year device life). A probabilistic sensitivity ana-
lysis was performed where uncertainty across all parameters
was considered simultaneously. For the probabilistic sensitiv-
ity analysis, we considered the uncertainty around human
capital cost. Finally, we also tested the assumption of varying
conventional locomotor training strategies by 10% (without
the inclusion of RT-exo) to assess the influence of varying
conventional locomotor strategies on budget impact as sce-
nario analysis.
Results
In the base case scenario for all hospital systems, offering
RT-exo for locomotor training decreased hospital costs as-
sociated with delivering locomotor training (Tables 3 & 4).
Providing RT-Exo for 10% of locomotor training sessions
over the course of the year results in decreased annual costs
associated with locomotor training; these savings ranged
from $649 (Facility D) to $4784 (Facility B) per annum.
The base case scenario had RT-Exo replacing a combin-
ation of all currently used robotic services, treadmill train-
ing with body-weight support, and over-ground training. It
also assumed that RT-Exo was idle 50% of the time.
Sensitivity analysis
The base case scenario was sensitive to several parameters,
such as the cost of a robotic exoskeleton, efficiency of robotic
exoskeleton use, training strategy substituted, and exoskel-
eton device life. Fig. 3 plots a series of one-way sensitivity
analyses showing the range of costs or savings associated
with a change in parameters across each facility. The greatest
savings were seen in Facility B ($14,704) where robotic
Table 1 Facility characteristics
Facility label Hospital structure Number of individuals with SCI/year
eligible for locomotor training
Number of sessions
offered per user
Number of locomotor training sessions
per year for individuals with SCI
A LTCH 172 16 2752
B IRF 248 16 3968
C LTCH 94 24 2256
D IRF 155 20 3105
Note: LTCH Long Term Acute Care Hospital, IRF Inpatient Rehabilitation Facility
Table 2 Locomotor strategy cost components in base case analysis
BWSTT Stationary robotic OGT- low cost OGT– high cost RT-Exo
Device cost $70,000 $350,000 $10,000 $225,000 $150,000
Maintenance contract $8500/yr × 5 years $15,000/yr maintenance × 5 years N/A $7500/yr × 5 years $10,000/yr
Lifespan 5 years 5 years 10 years 20 years 5 years
Personnel* 1 physical therapist (PT),
1 Exercise specialist†, 2 aides
1 PT, 1 aide 1 PT, 1 aide 1 PT 1 PT, 1 aide
Training requirement† 1 h 5 h 1 h 1 h 18 h
*Facility C specified using 1 PT and 3 exercise specialists
†We assumed two personnel trained per site
BWSTT, body-weight supported treadmill training; OGT, overground training; RT-Exo, robotic exoskeleton
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Table 3 Current and projected proportion of locomotor training in base case analysis
Current locomotor
training offerings
Current Market Share per locomotor strategy/
number of locomotor sessions*
Future Market Share per locomotor strategy
/number of locomotor sessions
Facility A, 2752
locomotor sessions/year
BWSTT 33% / 908 31% / 881
Stationary robotic 16% / 440 11% / 303
Over-ground training 51% / 1404 48% / 1293
Robotic Exoskeleton 10% / 275
Facility B, 3968
locomotor sessions/year
BWSTT 61% / 2420 56% / 2063
Stationary robotic 5% / 198 3% / 119
Over-ground training 34% / 1349 31% / 1309
Robotic Exoskeleton 10% / 397
Facility C, 2256
locomotor sessions/year
BWSTT 34% / 767 30% / 677
Stationary robotic 33% / 744 30% / 677
Over-ground training 33% / 744 30% / 677
Robotic Exoskeleton 10% / 226
Facility D, 3105
locomotor sessions/year
BWSTT 39% / 1211 36%/1118
Stationary robotic 10% / 311 7%/217
Over-ground training 51% / 1584 47%/1459
Robotic Exoskeleton 10%/311
* Number of locomotor sessions per user and locomotor strategy market share is based on facility averages and utilization rates. BWSTT, body-weight supported
treadmill training
Table 4 Current and projected market share per locomotor strategy
Facility Current locomotor
training offerings
Current Market Share: costs*
per locomotor strategy
Future Market Share: costs
per locomotor strategy
A: 2752 locomotor sessions/ year BWSTT $127,416 $119,700
Stationary robotic $66,056 $45,582
Over-ground training $104,171 $98,050
Robotic Exoskeleton $0 $31,486
Net difference = $294,818 (future costs) - $297,643 (current costs), Savings $2825
B: 3968 locomotor sessions/ year BWSTT $363,747 $333,941
Stationary robotic $31,105 $18,890
Over-ground training $107,064 $97,627
Robotic Exoskeleton $0 $46,674
Net difference = $497,133 (future costs) - $501,916 (current costs), Savings $4784
C: 2256 locomotor sessions/year BWSTT $124,178 $111,783
Stationary robotic $115,357 $103,889
Over-ground training $58,762 $52,903
Robotic Exoskeleton $0 $27,179
Net difference = $295,754 (future costs) - $298,297 (current costs), Savings $2543
D: 3105 locomotor sessions/year BWSTT $174,440 $161,030
Stationary robotic $47,037 $33,089
Over-ground training $119,009 $109,683
Robotic Exoskeleton $0 $35,587
Net difference = $338,993 (future costs) - $340,107 (current costs), Savings $1114
*Costs are in 2017 USD. BWSTT, body-weight supported treadmill training
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exoskeleton life was extended to 8 years, and the greatest cost
was seen in Facility B ($52,934) where robotic exoskeleton
adoption rate was limited to 10%. The probabilistic sensitivity
analysis simultaneously considered parameter uncertainty of
human capital costs (salary), device cost, and locomotor
training device substitution. The probabilistic sensitivity ana-
lysis produced a range of net budget impacts across facilities
from a net savings of $1247per annum in facility C to a net
cost of $1620 per annum in facility D. Full probabilistic sensi-
tivity analysis results are presented in Appendix 2.
We explored additional scenario analyses where, instead
of choosing to introduce RT-exo, we shift market share to
each of the conventional locomotor training strategies by
10%, e.g., in Facility A we assess how locomotor training
costs change after we shift from 33 to 43% BWSTT. When
stationary robotic and BWSTT are each increased by 10%
locomotor training costs increase at all facilities. This is be-
cause of the higher personnel cost in BWSTT and higher
device cost of stationary robotics relative to the overground
training cost. When conventional over-ground training is
increased by 10% it lowers costs at all facilities. Full scenario
analyses are presented in Appendix 3. For all facilities,
the savings from increasing market share to conven-
tional overground training are greater than the savings
from shifting market share to RT-exo.
Discussion
The base case analysis shows small savings that are sensitive
to cost or structural components of RT-exo. Despite the ex-
pense of RT-exo devices, savings related to a decrease in
staffing needs and training for the therapeutic device exist.
For hospital systems considering the addition of RT-exo as a
locomotor training strategy, those with a higher percentage
of human capital intensive strategies such as BWSTT may
experience reduced costs if the introduction of RT-exo sub-
stitutes for these locomotor training interventions. However,
the savings are very small with large degrees of uncertainty.
In the base case scenario, we assumed the robotic over-
ground exoskeleton adoption rate would be 50%. This esti-
mate may be too generous given two factors, the population
eligible for RT-exo and clinician acceptance of new technol-
ogy. RT-exo is a new technology that clinicians could choose
not to use for locomotor training despite hospital purchas-
ing decisions. Interestingly, the base case scenario was more
sensitive to assumptions on clinical utilization parameters
than device-specific parameters. For example, limiting the
RT-exo useful life to 3 years (versus 5) only resulted in an
increase in locomotor training cost per annum of between
$3847 and $7611 across facilities. However, if RT-exo was
adopted at a rate of 10%, i.e., the device is idle 90% of the
time (as opposed to the 50% used in our model), annual
Fig. 3 Results from One-Way Sensitivity Analyses. The effect of parameter variation on the base case (depicted as point estimate). Costs are in 2017 USD
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costs of locomotor training would increase between $32,096
and $52,934 across facilities. When considering all sensitivity
and scenario analyses the least costly alternative is when
over-ground training sessions are increased by 10%. This
makes intuitive sense because device costs and personnel
costs are lowest. Over-ground training is a well developed
and clinically integrated technology, therefore few efficien-
cies can be expected from changes in technological adoption
and further integration into clinical practice. Conversely,
further technological development stands to improve the
business case for RT-exo but barriers in adoption and inte-
gration can impair its efficiency. Issues of technological
adoption warrant additional attention.
Turchetti et al. provide a comprehensive overview of tech-
nology adoption with application to robotic devices in re-
habilitation [31]. The authors discuss barriers organized
around technological, behavioral, organizational, and eco-
nomic factors. Technological factors include ease of use,
level of training necessary for caregivers to master the tech-
nology, and the anthropomorphic design of the product
[31]. Of particular note with technological barriers is the
shift from roles once played by the clinician to the device
that may create behavioral barriers to adoption. Learning
new technologies requires effort on the part of clinicians, pa-
tient and caregivers, and resistance to change is a common
phenomenon. Organization factors may be manifested in
the need for redistribution of responsibilities and establish-
ing a new organizational balance. Economic barriers include
the dearth of cost-effectiveness data and the discordance be-
tween the timing required for purchasing decisions and the
rate of change concerning reimbursement.
Another barrier to adoption is the different perspectives
on the value added by the new technology suggesting the
need for further economic studies that consider multiple
perspectives in order to address the interests of all stake-
holders [31]. Swank and colleagues report on the feasibility
of integrating RT-exo as a part of inpatient rehabilitation for
an individual with SCI and illuminate on many aspects of
RT-exo adoption identified above [37]. Of note was the need
for additional training for intra- and inter-physical therapist
consistency with use of RT-exo despite being certified in use
of the device. Working with hospital administrators and
support staff was needed to address workflow issues such as
optimizing device sizing and adjust settings prior to the
rehabilitation visit.
We did not quantify several key considerations regarding
RT-exo in this analysis. Hospital systems may invest in RT-
exo as a means of building or maintaining their reputation
as a leader in the use of cutting-edge technology. In this
model, RT-exo is considered only as a substitute for loco-
motor training in the rehabilitation setting; however, there is
potential for RT-exo to augment some community mobility.
Devices such as RT-exo are likely to decrease in cost with
greater competition in the market [38]. Numerous robotic
device companies are entering the market with several at
substantially lower price points than the price weight used
for this investigation, e.g., $30,000 instead of $150,000 [39].
One device manufacturer anticipates being able to produce
RT-exos at $10,000 – $15,000, [39] which would be compar-
able with the price weight used for our low cost OGT de-
vice. With the use of new medical devices, there is a device-
operator interaction known as the ‘learning curve” effect
[40, 41] during which inefficiencies are more likely; this is
arguably the state that we are currently in with respect to
RT-exo use in rehabilitation and we anticipate an improved
business case in the future.
Study limitations
This project did not take into account differences in
locomotor training effectiveness between alternatives.
There is no strong evidence showing the superiority or
non-inferiority of RT-exo. The evidence for the com-
parative effectiveness of robotic overground exoskeleton
for locomotor training in SCI is limited, but several pilot
studies show promising results [10, 23], and multiple
clinical studies are underway or in development that will
add to the evidence base (ClinicalTrials.gov Identifier:
NCT03340792, NCT03477123, NCT02322125, NCT0344
3700). Therefore, the findings of this BIA must be inter-
preted with caution because we assume non-inferiority. In
addition, there is limited data on the risks to users with SCI
and personnel associated with locomotor training for RT-exo
relative to other locomotor training strategies [12]. The retro-
spective study design provides estimates for the number of
individuals with SCI who received locomotor training therap-
ies in 2017. Individuals with high cervical incomplete injuries
who do not have upper extremity strength are not al-
ways eligible to use all RT-exo systems, but they are
eligible to receive locomotor training with one RT-exo
device and with other interventions. Therefore the
volume of eligible patients may be lower than our esti-
mates suggest; however, devices under development
are designed to be used with individuals who have
higher levels of SCI [42]. We may have overestimated
eligibility across therapy types due to varying eligibility
criteria specific to each device (e.g., robotic exoskel-
eton device fit versus BWSTT fit criteria).
Conclusions
The assessment of economic efficiency-with robotic exo-
skeleton is in its infancy. Our model provides a frame-
work upon which economic studies can build. Utilizing
RT-exo for locomotor training may be an efficient use of
hospital resources if key assumptions concerning efficacy
hold true and the technology is adopted within the
health system; however, a large degree of uncertainty
surrounds our estimates as evidence for differences in
the effectiveness of among approaches is limited.
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Appendix 1
Table 5 Unit costs and associated sources
Component Cost/unit Assumptions and sources
Locomotor strategies
RT-exo $150,000 5 year life-span+Annual maintenance contract
($10,000) × 5 years
Litegait - overground training $10,000 Rehabilitaton hospital purchasing department
Zero G track system $225,000 Rehabilitaton hospital purchasing department
+Annual maintenance contract
($7500) × 5 years
Treadmill training with body-weight
support (BWS) - treadmill and
harness system
$70,000 Rehabilitaton hospital purchasing department
+Annual maintenance contract
($8500) × 5 years
Lokomat $350,000 $350,000 + Annual maintenance contract
($15,000) × 5 years
Rehabilitaton hospital purchasing department
Personnel
PT $53.95 – Facility A 2017 BLS mean hourly rate by state + 30%
benefits https://www.bls.gov/ooh/healthcare
/physical-therapists.htm
$56.68 – Facility B $41.50*0.3 – Facility A
$58.08 – Facility C $43.60 + 0.3 - Facility B
$51.58 – Facility D $44.68 + 0.3 - Facility C
$39.69 + 0.3 – Facility D
PT Assistant $33.66 – Facility A 2017 BLS mean hourly rate by state + 30%
benefits
$36.30 – Facility B 25.89 + 30% benefits – Facility A
$43.68 – Facility C 27.92 + 30% benefits – Facility B
$34.61 – Facility D 33.60 + 30% benefits – Facility C
26.62 + 30% benefits – Facility D
Exercise specialist $31.94 – Facility A Exercise physiologist
$34.46 – Facility B 2017 BLS mean hourly rate by state + 30%
benefits
$28.90 – Facility C $24.57 - Facility A
$31.87 – Facility D $26.51- Facility B
$22.23 - Facility C
$23.99 - Facility D
PT Aide/tech $17.04 – Facility A 2017 BLS mean hourly rate by state + 30%
benefits
$19.44 – Facility B $13.11+ 30% benefits – Facility A
$16.76 – Facility C $14.95+ 30% benefits – Facility B
$20.15 – Facility D $12.89+ 30% benefits – Facility C
$15.50 + 30% benefits – Facility D
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Appendix 2
Table 6 Full results of Probabilistic sensitivity analysis
Mean (SD) 95% CI
Facility A
Current cost 318,727.09 (38,750.52) 244,101.81, 396,054.92
Future cost 319,901.66 (37,082.70) 248,223.86, 392,349.78
Difference 1174.56 (13,552.87) −23,305.15, 30,106.35
Facility B
Current cost 340,331.06 (39,527.96) 264,223.77, 418,017.98
Future cost 340,533.79 (37,800.31) 266,498.82, 414,476.83
Difference 202.73 (13,430.07) −24,508.92, 28,976.15
Facility C
Current cost 355,740.28 (39,565.62) 279,999.34, 432,895.62
Future cost 354,493.63 (37,927.97) 280,420.54, 428,026.15
Difference − 1246.65 (13,663.67) − 26,749.97, 27,183.83
Facility D
Current cost 318,888.07 (39,101.88) 242,958.61, 395,990.05
Future cost 320,508.13 (37,354.01) 247,590.25, 393,909.77
Difference 1620.06 (13,422.23) − 7404.26, 31,122.70
CI Credible Interval
Appendix 3





Current Market Share per
locomotor strategy/number
of locomotor sessions*




- 10% increase in body
weight support




- 10% increase in Stationary
robotic












33% / 908 43% / 1183 28% / 771 28% / 771
Stationary
robotic
16% / 440 11% / 303 26% / 716 11% / 303
Over-ground
training







61% / 2420 71% / 2817 56% / 2222 55% / 2182
Stationary
robotic
5% / 198 1% / 40 15% / 595 1% / 40
Over-ground
training







34% / 767 43% / 970 29% / 654 29% / 654
Stationary
robotic
33% / 744 29% / 654 43% / 970 28% / 632
Over-ground
training







39% / 1211 49% / 1521 36% / 1118 34% / 1056
Stationary
robotic
10% / 311 5% / 155 17% / 528 5% / 155
Over-ground 51% / 1584 46% / 1428 47% / 1459 61% / 1894
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Current Market Share per
locomotor strategy/number
of locomotor sessions*




- 10% increase in body
weight support




- 10% increase in Stationary
robotic























BWS $127,416 $165,994 $108,127 $108,125
Stationary
robotic
$66,056 $45,582 $107,004 $45,581
Over-ground
training
$104,171 $93,969 $93,969 $124,568
subtotal $297,643 $305,545 $309,099 $278,274




BWS $363,747 $423,360 $333,941 $327,980
Stationary
robotic
$31,105 $6674 $92,182 $6674
Over-ground
training
$107,064 $88,190 $91,336 $138,520
Subtotal $501,916 $518,224 $517,459 $473,175




BWS $124,178 $160,172 $108,061 $108,061
Stationary
robotic
$115,357 $100,446 $148,656 $97,002
Over-ground
training
$58,762 $49,384 $49,384 $75,777
subtotal $298,297 $310,001 $306,101 $280,840




BWS $168,627 $211,837 $155,665 $147,023
Stationary
robotic
$47,037 $23,791 $79,581 $23,791
Over-ground
training
$119,009 $107,352 $109,683 $142,323
subtotal $334,673 $342,980 $334,929 $142,323
Net difference $8307 $10,256 $–21,537
* negative (−) values denote a net saving
Pinto et al. Journal of NeuroEngineering and Rehabilitation            (2020) 17:4 Page 11 of 13
Abbreviations
BIA: Budget Impact Analysis; BWSTT: Body-weight supported treadmill
training; IRF: Inpatient Rehabilitation Facility; LTCH: Long Term Acute Care
Hospital; OGT: Overground training; PT: Physical therapist; RT: Robotic






DP, AJ, AWH conceived of the study, JB, SHC, SC, EFF, CF, CT, CKM, HT, AJ
provided site specific data on utilization and costs, DP and MG performed all
analyses and data interpretation, DP wrote initial draft of manuscript, All
authors provided critical feedback on the manuscript. All authors read and
provided approval of the final manuscript.
Authors’ information
Daniel Pinto, PT, PhD (corresponding author: 414.288.4495 phone, d.
pinto@marquette.edu), Assistant Professor, Department of Physical Therapy,
Marquette University.
Funding
The National Institute on Disability, Independent Living, and Rehabilitation
Research provided funding through the Midwest Regional SCI Model System
(90SI5009), the Rocky Mountain Regional Spinal Injury System (90SI5015), the
Southeastern Regional Spinal Cord Injury Model System at Shepherd Center
(90SI5016), and the Texas Model Spinal Cord Injury System at TIRR Memorial
Hermann (90SI5027).
Availability of data and materials
The dataset used and analyzed during the current study are available from
the corresponding author upon request.





The authors declare that they have no competing interests.
Author details
1Department of Physical Therapy, College of Health Sciences, Marquette
University, Milwaukee, USA. 2Department of Medical and Social Sciences,
Feinberg School of Medicine, Northwestern University, Evanston, USA.
3College of Nursing, Marquette University, Milwaukee, USA. 4Shirley Ryan
Ability Lab, Chicago, USA. 5Department of Physical Therapy and Human
Movement Sciences, Feinberg School of Medicine, Northwestern University,
Evanston, USA. 6Department of Physical Medicine and Rehabilitation
McGovern Medical School, University of Texas Health Science Center at
Houston, Houston, USA. 7SCI Research, Craig Hospital, Englewood, USA.
8Department of Physical Medicine and Rehabilitation, University of Colorado,
Denver, USA. 9Spinal Cord Injury Research at the Shepherd Center, Atlanta,
Georgia. 10Division of Physical Therapy, Department of Rehabilitation
Medicine, Emory University School of Medicine, Atlanta, Georgia. 11Craig
Hospital, Englewood, USA. 12Max Nader Center for Rehabilitation
Technologies & Outcomes Research, Chicago, USA. 13Office of Translational
Research, Shirley Ryan Ability Lab, Chicago, USA. 14Spinal Cord Injury and
Disability Research, TIRR Memorial Herman, Houston, USA. 15Pediatrics and
Physical Medicine and Rehabilitation McGovern Medical School, University of
Texas Health Science Center, Houston, USA. 16Northwestern University,
Evanston, USA. 17Center for Rehabilitation Outcomes Research, Department
of PM&R, Feinberg School of Medicine, Northwestern University, Evanston,
USA.
Received: 28 June 2019 Accepted: 22 December 2019
References
1. National Spinal Cord Injury Statistical Center. Spinal cord injury (SCI) facts
and figures at a glance. Birmingham, Alabama: University of Alabama at
Birmingham; 2019.
2. Sezer N, Akkus S, Ugurlu FG. Chronic complications of spinal cord injury.
World J Orthop. 2015;6(1):24–33.
3. Dittuno PL, Ditunno JF Jr. Walking index for spinal cord injury (WISCI II):
scale revision. Spinal Cord. 2001;39(12):654–6.
4. Calhoun CL, Schottler J, Vogel LC. Recommendations for mobility in children
with spinal cord injury. Top Spinal Cord Inj Rehabil. 2013;19(2):142–51.
5. Krebs HI, Ladenheim B, Hippolyte C, Monterroso L, Mast J. Robot-assisted
task-specific training in cerebral palsy. Dev Med Child Neurol. 2009;51(Suppl
4):140–5.
6. Arya KN, Pandian S, Verma R, Garg RK. Movement therapy induced neural
reorganization and motor recovery in stroke: a review. J Bodyw Mov Ther.
2011;15(4):528–37.
7. Fasoli SE, Krebs HI, Hogan N. Robotic technology and stroke rehabilitation:
translating research into practice. Top Stroke Rehabil. 2004;11(4):11–9.
8. Turchetti G, Labella B, Bellelli S, Cannizzo S, Palla I, Mazzoleni S, et al.
Innovation in rehabilitation technology: technological opportunities and
socioeconomic implications – a theoretical model. Int J Healthcare Technol
Manag. 2009;10(4):245–61.
9. Masiero S, Armani M, Rosati G. Upper-limb robot-assisted therapy in
rehabilitation of acute stroke patients: focused review and results of new
randomized controlled trial. J Rehabil Res Dev. 2011;48(4):355–66.
10. Chang SH, Afzal T, Group TSCE, Berliner J, Francisco GE. Exoskeleton-assisted
gait training to improve gait in individuals with spinal cord injury: a pilot
randomized study. Pilot Feasibility Stud. 2018;4:62.
11. Food and Drug Administration. PART 890—PHYSICAL MEDICINE DEVICES
Food and Drug Administration, HHS.; 2015 Tuesday, February 24, 2015.
12. Miller LE, Zimmermann AK, Herbert WG. Clinical effectiveness and safety of
powered exoskeleton-assisted walking in patients with spinal cord injury:
systematic review with meta-analysis. Med Devices (Auckl). 2016;9:455–66.
13. Federici S, Meloni F, Bracalenti M, De Filippis ML. The effectiveness of
powered, active lower limb exoskeletons in neurorehabilitation: a systematic
review. NeuroRehabilitation. 2015;37(3):321–40.
14. Nam KY, Kim HJ, Kwon BS, Park JW, Lee HJ, Yoo A. Robot-assisted gait
training (Lokomat) improves walking function and activity in people with
spinal cord injury: a systematic review. J Neuroeng Rehabil. 2017;14(1):24.
15. Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J. Robot-
assisted gait training in multiple sclerosis: a pilot randomized trial. Mult
Scler. 2008;14(2):231–6.
16. Hidler J, Nichols D, Pelliccio M, Brady K, Campbell DD, Kahn JH, et al.
Multicenter randomized clinical trial evaluating the effectiveness of the
Lokomat in subacute stroke. Neurorehabil Neural Repair. 2009;23(1):5–13.
17. Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted,
body weight supported treadmill training. Neurorehabil Neural Repair. 2008;
22(6):661–71.
18. Picelli A, Melotti C, Origano F, Waldner A, Fiaschi A, Santilli V, et al. Robot-
assisted gait training in patients with Parkinson disease: a randomized
controlled trial. Neurorehabil Neural Repair. 2012;26(4):353–61.
19. Schwartz I, Sajin A, Moreh E, Fisher I, Neeb M, Forest A, et al. Robot-assisted
gait training in multiple sclerosis patients: a randomized trial. Mult Scler.
2012;18(6):881–90.
20. Vaney C, Gattlen B, Lugon-Moulin V, Meichtry A, Hausammann R, Foinant D,
et al. Robotic-assisted step training (lokomat) not superior to equal intensity
of over-ground rehabilitation in patients with multiple sclerosis.
Neurorehabil Neural Repair. 2012;26(3):212–21.
21. Cheung EYY, Ng TKW, Yu KKK, Kwan RLC, Cheing GLY. Robot-assisted
training for people with spinal cord injury: a meta-analysis. Arch Phys Med
Rehabil. 2017;98(11):2320–31 e12.
22. Tefertiller C, Pharo B, Evans N, Winchester P. Efficacy of rehabilitation
robotics for walking training in neurological disorders: a review. J Rehabil
Res Dev. 2011;48(4):387–416.
23. Sale P, Russo EF, Scarton A, Calabro RS, Masiero S, Filoni S. Training for
mobility with exoskeleton robot in person with spinal cord injury: a pilot
study. Eur J Phys Rehabil Med. 2018;54(5):745-51.
Pinto et al. Journal of NeuroEngineering and Rehabilitation            (2020) 17:4 Page 12 of 13
24. Manns PJ, Hurd C, Yang JF. Perspectives of people with spinal cord injury
learning to walk using a powered exoskeleton. J Neuroeng Rehabil. 2019;
16(1):94.
25. Fritz H, Patzer D, Galen SS. Robotic exoskeletons for reengaging in everyday
activities: promises, pitfalls, and opportunities. Disabil Rehabil. 2019;41(5):
560-3.
26. Sorenson C, Drummond M, Bhuiyan KB. Medical technology as a key driver
of rising health expenditure: disentangling the relationship. Clinicoecon
Outcomes Res. 2013;5:223–34.
27. Drummond M, Tarricone R, Torbica A. Assessing the added value of health
technologies: reconciling different perspectives. Value Health. 2013;16(1):S7–13.
28. Moses H 3rd, Matheson DH, Dorsey ER, George BP, Sadoff D,
Yoshimura S. The anatomy of health care in the United States. JAMA.
2013;310(18):1947–63.
29. Neumannm PJ, Weinstein MC. The Diffusion of New Technology: Costs and
Benefits to Health Care. In: Gelijns AC, Halm EA, editors. The Changing
Economics of Medical Technology. Washington, DC: National Academies
Press (US); 1991. p. 21.
30. Krebs HI, Hogan N, Aisen ML, Volpe BT. Robot-aided neurorehabilitation.
IEEE Trans Rehabil Eng. 1998;6(1):75–87.
31. Turchetti G, Vitiello N, Trieste L, Romiti S, Geisler E, Micera S. Why
effectiveness of robot-mediated neurorehabilitation does not necessarily
influence its adoption. IEEE Rev Biomed Eng. 2014;7:143–53.
32. Esquenazi A. Comment on "assessing effectiveness and costs in robot-
mediated lower limbs rehabilitation: a meta-analysis and state of the art". J
Healthc Eng. 2018;2018:7634965.
33. Morrison SA. Financial feasibility of robotics in Neurorehabilitation. Top
Spinal Cord Inj Rehabil. 2011;17(1):77–81.
34. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M,
et al. Budget impact analysis-principles of good practice: report of the
ISPOR 2012 budget impact analysis good practice II task force. Value Health.
2014;17(1):5–14.
35. R Core Team. A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2013.
36. Consortium YHE. Base Case Analysis [online] 2016 [Available from: https://
www.yhec.co.uk/glossary/base-case-analysis/.
37. Swank C, Sikka S, Driver S, Bennett M, Callender L. Feasibility of integrating
robotic exoskeleton gait training in inpatient rehabilitation. Disabil Rehabil
Assist Technol. 2019;19:1-9.
38. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and
drugs--same or different? Value Health. 2009;12(4):402–4.
39. Wilson M. A Budget Exoskeleton Allows Paraplegics To Walk–For The Price
Of A Car2016 2/1/2016. Available from: https://www.fastcompany.com/3056
049/a-budget-exoskeleton-allows-parapalegics-to-walk-for-the-price-of-a-car.
40. Cook JA, Ramsay CR, Fayers P. Using the literature to quantify the learning
curve: a case study. Int J Technol Assess Health Care. 2007;23(2):255–60.
41. Taylor RS, Iglesias CP. Assessing the clinical and cost-effectiveness of
medical devices and drugs: are they that different? Value Health. 2009;
12(4):404–6.
42. Gorgey AS. Robotic exoskeletons: the current pros and cons. World J
Orthop. 2018;9(9):112–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Pinto et al. Journal of NeuroEngineering and Rehabilitation            (2020) 17:4 Page 13 of 13
